

Acyclovir Ointment

Products Affected

- *acyclovir ointment 5 % external*

Details

Criteria	Use of oral acyclovir or Abreva in the previous 130 days
-----------------	--

Adcirca

Products Affected

- *tadalafil (pah) tablet 20 mg oral*

Details

Criteria	Use of sildenafil in previous 30 days
----------	---------------------------------------

Albenza

Products Affected

- *albendazole tablet 200 mg oral*

Details

Criteria	Requires use of pyrantel or ivermectin for at least 3 days. When ST therapy requirements are not met, the criteria in the PA guideline must be met for approval.
-----------------	--

Albuterol Nebulizers

Products Affected

- *albuterol sulfate nebulization solution 0.63 mg/3ml inhalation*
- *albuterol sulfate nebulization solution 1.25 mg/3ml inhalation*

Details

Criteria	Use of albuterol 0.083% in the previous 14 days. Patients < 18 years of age are not subject to ST.
-----------------	--

Atomoxetine

Products Affected

- *atomoxetine hcl capsule 10 mg oral*
- *atomoxetine hcl capsule 100 mg oral*
- *atomoxetine hcl capsule 18 mg oral*
- *atomoxetine hcl capsule 25 mg oral*
- *atomoxetine hcl capsule 40 mg oral*
- *atomoxetine hcl capsule 60 mg oral*
- *atomoxetine hcl capsule 80 mg oral*

Details

Criteria	Use of 2 formulary CNS stimulants for ADHD in the previous 90 days
----------	--

Atovaquone Suspension

Products Affected

- *atovaquone suspension 750 mg/5ml oral*

Details

Criteria	Use of sulfamethoxazole/trimethoprim in the previous 130 days
-----------------	---

Azopt

Products Affected

- AZOPT SUSPENSION 1 %
OPHTHALMIC

Details

Criteria	Use of dorzolamide or dorzolamide/timolol in the previous 130 days
----------	--

Celecoxib

Products Affected

- *celecoxib capsule 100 mg oral*
- *celecoxib capsule 200 mg oral*
- *celecoxib capsule 400 mg oral*
- *celecoxib capsule 50 mg oral*

Details

Criteria	Requires use of 3 different NSAID's. When ST therapy requirements are not met, the criteria in the PA guideline must be met for approval.
-----------------	---

Ciclopirox Shampoo

Products Affected

- *ciclopirox shampoo 1 % external*

Details

Criteria	Use of Ketoconazole Shampoo for 10 days within the previous 60 days.
-----------------	--

Ciclopirox Suspension/Cream

Products Affected

- *ciclopirox olamine cream 0.77 % external external*
- *ciclopirox olamine suspension 0.77 %*

Details

Criteria	Use of any one of the following for 10 days in the previous 60 days: OTC Clotrimazole Solution/Cream 1%, OTC Miconazole Cream/Ointment
-----------------	--

Clonidine Patches

Products Affected

- *clonidine patch weekly 0.1 mg/24hr transdermal*
- *clonidine patch weekly 0.2 mg/24hr*
- *clonidine patch weekly 0.3 mg/24hr transdermal*

Details

Criteria	Use of clonidine tablets for at least 30 days within the past 130 days.
-----------------	---

Clotrimazole (Rx)

Products Affected

- *clotrimazole cream 1 % external*
- *clotrimazole solution 1 % external*

Details

Criteria	Use of OTC Clotrimazole Cream/Solution 1% for 10 days in the previous 60 days
-----------------	---

Combigan

Products Affected

- **COMBIGAN SOLUTION 0.2-0.5 %
OPHTHALMIC**

Details

Criteria	Use of 1 of the following for at least 15 days in the previous 130 days: Brimonidine Ophth Solution, Timolol Maleate Ophth Solution
-----------------	--

DPP4

Products Affected

- **JANUMET TABLET 50-1000 MG ORAL**
- **JANUMET TABLET 50-500 MG ORAL**
- **JANUMET XR TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG ORAL**
- **JANUMET XR TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG ORAL**
- **JANUMET XR TABLET EXTENDED RELEASE 24 HOUR 50-500 MG ORAL**
- **JANUVIA TABLET 100 MG ORAL**
- **JANUVIA TABLET 25 MG ORAL**
- **JANUVIA TABLET 50 MG ORAL**

Details

Criteria	Use of metformin or combination metformin products for at least 60 days in the previous 130 days
-----------------	--

Ezetimibe

Products Affected

- *ezetimibe tablet 10 mg oral*

Details

Criteria	Use of BOTH simvastatin and atorvastatin in the previous 130 days
-----------------	---

Febuxostat

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Use of allopurinol in the previous 130 days
-----------------	---

GLP-1 Receptor Agonists

Products Affected

- **OZEMPIC SOLUTION PEN-INJECTOR 0.25 OR 0.5 MG/DOSE SUBCUTANEOUS**
- **OZEMPIC SOLUTION PEN-INJECTOR 1 MG/DOSE SUBCUTANEOUS**
- **VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS**

Details

Criteria	Use of metformin or combination metformin products for at least 60 days in the previous 130 days
-----------------	--

Griseofulvin

Products Affected

- *griseofulvin microsize suspension 125 mg/5ml oral*
- *griseofulvin microsize tablet 500 mg oral*
- *griseofulvin ultramicrosize tablet 125 mg*
- *griseofulvin ultramicrosize tablet 250 mg oral*

Details

Criteria	Use of any one: terbinafine tablets, ketoconazole tablets, fluconazole tablets/suspension, itraconazole capsules/solution for at least 7 days within the last 60 days. When step therapy requirements are not met, the criteria in the PA guideline must be met for approval.
-----------------	---

Isotretinoin

Products Affected

- MYORISAN CAPSULE 10 MG ORAL
- MYORISAN CAPSULE 20 MG ORAL
- MYORISAN CAPSULE 30 MG ORAL
- MYORISAN CAPSULE 40 MG ORAL
- ZENATANE CAPSULE 10 MG ORAL
- ZENATANE CAPSULE 20 MG ORAL
- ZENATANE CAPSULE 30 MG ORAL
- ZENATANE CAPSULE 40 MG ORAL

Details

Criteria	Use of doxycycline or minocycline for at least 30 days in the previous 130 days
-----------------	---

Ketoconazole Cream

Products Affected

- *ketoconazole cream 2 % external*

Details

Criteria	Use of any one of the following for 10 days in the previous 60 days: OTC Clotrimazole Solution/Cream 1%, OTC Miconazole Cream/Ointment, OTC Tolnaftate Cream 1%, OTC Terbinafine Cream 1%, OTC Butenafine Cream 1%
-----------------	--

Levalbuterol HFA

Products Affected

- *levalbuterol tartrate aerosol 45 mcg/act inhalation*

Details

Criteria	Use of Ventolin HFA
----------	---------------------

Lice/Scabicides

Products Affected

- *malathion lotion 0.5 % external*
- *spinosad suspension 0.9 % external*

Details

Criteria	Use of permethrin or pyrethrin in the previous day
-----------------	--

Naproxen Suspension

Products Affected

- *naproxen suspension 125 mg/5ml oral*

Details

Criteria	Use of ibuprofen suspension for 15 days within the previous 130 days
-----------------	--

Nasal Steroids

Products Affected

- *flunisolide solution 25 mcg/act (0.025%) nasal*
- *fluticasone propionate suspension 50 mcg/act nasal*
- *mometasone furoate suspension 50 mcg/act*

Details

Criteria	Use of 2 of the following agents in the previous 130 days: Flonase OTC, Rhinocort OTC, or Nasacort OTC
-----------------	--

Norethindrone

Products Affected

- *norethindrone acetate tablet 5 mg oral*

Details

Criteria	Use of medroxyprogesterone acetate tablets for 30 days in the previous 130 days.
-----------------	--

Olopatadine Ophthalmic Solution

Products Affected

- *olopatadine hcl solution 0.1 % ophthalmic*

Details

Criteria	Use of ketotifen ophthalmic solution in the previous 15 days
-----------------	--

Omega 3

Products Affected

- *omega-3-acid ethyl esters capsule 1 gm oral*

Details

Criteria	Use of OTC Fish Oil for at least 60 days in the previous 130 days.
-----------------	--

Ophthalmic antihistamines

Products Affected

- *azelastine hcl solution 0.05 % ophthalmic*

Details

Criteria	Use of ketotifen ophthalmic in the previous 130 days
-----------------	--

Overactive Bladder

Products Affected

- *tolterodine tartrate er capsule extended release 24 hour 2 mg oral*
- *tolterodine tartrate er capsule extended release 24 hour 4 mg oral*
- *tolterodine tartrate tablet 1 mg oral*
- *tolterodine tartrate tablet 2 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*
- *trospium chloride tablet 20 mg oral*

Details

Criteria	Use of oxybutynin IR/ER for at least 30 days within the previous 130 days.
-----------------	--

Paricalcitol

Products Affected

- *paricalcitol capsule 1 mcg oral*
- *paricalcitol capsule 2 mcg oral*
- *paricalcitol capsule 4 mcg oral*

Details

Criteria	Use of calcitriol in the previous 130 days
-----------------	--

Phosphate Binders

Products Affected

- **AURYXIA TABLET 1 GM 210 MG(Fe)** • *sevelamer carbonate tablet 800 mg oral*
ORAL

Details

Criteria	Use of calcium acetate for at least 30 days within the previous 130 days.
-----------------	---

Ramelteon

Products Affected

- *ramelteon tablet 8 mg oral*

Details

Criteria	Use of zolpidem AND zaleplon in the previous 130 days
-----------------	---

Ribasphere

Products Affected

- RIBASPHERE CAPSULE 200 MG
- RIBASPHERE TABLET 200 MG ORAL

Details

Criteria	Paid claim for a direct-acting antiviral for Hepatitis C or Pegasys in the previous 5 days to assure that patients are taking ribavirin with other appropriate hepatitis C medications and not as monotherapy.
-----------------	--

Rosiglitazone

Products Affected

- AVANDIA TABLET 2 MG ORAL
- AVANDIA TABLET 4 MG ORAL

Details

Criteria	Use of both metformin and pioglitazone in the previous 130 days
-----------------	---

Rosuvastatin

Products Affected

- *rosuvastatin calcium tablet 10 mg oral*
- *rosuvastatin calcium tablet 20 mg oral*
- *rosuvastatin calcium tablet 40 mg oral*
- *rosuvastatin calcium tablet 5 mg oral*

Details

Criteria	Use of atorvastatin for at least 60 days in the previous 130 days
-----------------	---

Savella

Products Affected

- **SAVELLA TABLET 100 MG ORAL**
- **SAVELLA TABLET 12.5 MG ORAL**
- **SAVELLA TABLET 25 MG ORAL**
- **SAVELLA TABLET 50 MG ORAL**
- **SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL**

Details

Criteria	Use of duloxetine for at least 60 days in the previous 130 days
----------	---

SGLT2

Products Affected

- **SEGLUROMET TABLET 2.5-1000 MG ORAL**
- **SEGLUROMET TABLET 2.5-500 MG ORAL**
- **SEGLUROMET TABLET 7.5-1000 MG ORAL**
- **SEGLUROMET TABLET 7.5-500 MG ORAL**
- **STEGLATRO TABLET 15 MG ORAL**
- **STEGLATRO TABLET 5 MG ORAL**

Details

Criteria	Use of metformin or combination metformin products for at least 60 days in the previous 130 days
-----------------	--

Stiolto

Products Affected

- **STIOLTO RESPIMAT AEROSOL
SOLUTION 2.5-2.5 MCG/ACT
INHALATION**

Details

Criteria	Use of ONE of the following: Incruse Ellipta or Anoro Ellipta in the previous 130 days
-----------------	--

Timolol Gel

Products Affected

- *timolol maleate gel forming solution 0.25 % ophthalmic*
- *timolol maleate gel forming solution 0.5 % ophthalmic*

Details

Criteria	Use of Timolol Solution for 15 days in the previous 130 days
-----------------	--

Topical Calcineurin Inhibitors

Products Affected

- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

Details

Criteria	Use of 2 different topical corticosteroids in the previous 130 days
-----------------	---

Topical Retinoids

Products Affected

- *adapalene cream 0.1 % external*
- **AVITA CREAM 0.025 % EXTERNAL**
- **AVITA GEL 0.025 % EXTERNAL**
- *tretinoin cream 0.025 % external*
- *tretinoin cream 0.05 % external*
- *tretinoin cream 0.1 % external*
- *tretinoin gel 0.01 % external*
- *tretinoin gel 0.025 % external*

Details

Criteria	Use of OTC Differin 0.1% Gel in the previous 130 days
----------	---

Topical Steroids

Products Affected

- *clobetasol propionate cream 0.05 % external*
- *clobetasol propionate ointment 0.05 % external*
- *clobetasol propionate gel 0.05 % external*

Details

Criteria	Use of 1 of the following for at least 10 days within the past 60 days: AUG Betamethasone Dip Gel 0.05%, AUG Betamethasone Dip Lotion 0.05%, AUG Betamethasone Dip Ointment 0.05%, Halobetasol 0.05% Cream, Halobetasol 0.05% Ointment
-----------------	---

Zafirlukast

Products Affected

- *zafirlukast tablet 10 mg oral*
- *zafirlukast tablet 20 mg oral*

Details

Criteria	Use of montelukast for at least 30 days in the previous 130 days
-----------------	--
